AstraZeneca Under Fraud Probe Related to Lung Cancer Medication
AstraZeneca, whose China president is under investigation, is facing scrutiny for suspected medical insurance fraud linked to the sales of lung cancer medication Tagrisso. Reports from Chinese media indicate an official investigation into sales representatives in Shenzhen regarding potential insurance fraud.
The National Healthcare Security Administration (NHSA) began the probe in early 2022, alleging that some AstraZeneca employees manipulated patient genetic test results to facilitate fraudulent medication purchases through insurance. The investigation has led to multiple arrests, including that of Zuo Yinquan, responsible for sales in several provinces.
Sentences for implicated staff, including Kang Yuling, have raised the stakes. Confessions from employees reveal pressure to meet sales targets, leading to unethical practices in obtaining necessary medication.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.